Loading the section…
The price of Agios Pharmaceuticals, Inc. (AGIO) on October 9, 2026 is 31.81 USD, -0.34% on the day. Over 52 weeks the stock traded between 22.24 USD and 46.00 USD; the price now sits 40% of the way up that range. Over the past year the price changed by -25.33%. Market capitalization is 1.89 billion USD, rank 78 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 29 October 2026 · Earnings calendar
Change over the period shown (line colour): −22.26 %
Agios Pharmaceuticals, Inc. trades on Nasdaq under the ticker AGIO. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks AGIO has traded between 22.24 $ and 46.00 $. As of 9 October 2026 the price stood 40.28 % of the way from the 52-week low to the high.
Over one year AGIO shares fell 25.33 %; over six months they fell 3.37 %. Volatility over 90 days is 50.40 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 28.6, above the sector median of 4.0. Price to book is 1.7, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 31.85 | 32.15 | 31.52 | 31.81 | 835,700 |
| 8 October 2026 | 31.46 | 32.32 | 31.16 | 31.92 | 2M |
| 7 October 2026 | 31.37 | 32.27 | 31.07 | 31.79 | 2M |
| 6 October 2026 | 31.49 | 32.03 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
No events for this security recently.
Agios Pharmaceuticals, Inc. (AGIO) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 66.0m $, net income was -422.6m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:88 SIDNEY STREET, CAMBRIDGE, MA, 02139, US
Agios Pharmaceuticals, Inc. reported revenue of 66M $ and a net loss of 423M $ over the last four quarters. Net margin is −639.84 %. Revenue changed by +78.34 % year over year. Earnings per share are −7.26 $. Market capitalisation is 1.9B $.
AGIO has a return on equity of −38.10 %, above the sector median of −41.68 %. Return on assets is −35.66 %, below the sector median of −32.11 %. Operating margin is −719.97 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 30.79 |
| 31.72 |
| 1M |
| 5 October 2026 | 31.65 | 31.76 | 30.78 | 31.25 | 808,700 |
| 2 October 2026 | 32.82 | 32.82 | 31.65 | 31.80 | 569,900 |
| 1 October 2026 | 33.25 | 33.73 | 32.42 | 32.48 | 2M |
| 30 September 2026 | 33.67 | 34.06 | 33.20 | 33.25 | 2M |
| 29 September 2026 | 33.21 | 33.55 | 32.70 | 33.30 | 416,400 |
| 28 September 2026 | 32.53 | 34.12 | 32.35 | 33.42 | 1M |
| 25 September 2026 | 32.93 | 33.33 | 32.54 | 32.58 | 996,500 |
| 24 September 2026 | 34.02 | 34.13 | 31.37 | 32.90 | 2M |
| 23 September 2026 | 34.85 | 35.09 | 34.09 | 34.19 | 752,500 |
| 22 September 2026 | 34.19 | 35.36 | 33.88 | 34.97 | 1M |
| 21 September 2026 | 33.70 | 34.14 | 33.30 | 33.95 | 884,500 |
| 18 September 2026 | 33.29 | 33.40 | 32.77 | 33.07 | 2M |
| 17 September 2026 | 33.42 | 34.30 | 33.19 | 33.61 | 956,700 |
| 16 September 2026 | 32.89 | 33.75 | 32.74 | 32.95 | 863,500 |
| 15 September 2026 | 33.23 | 33.48 | 32.22 | 32.81 | 1M |
| 14 September 2026 | 33.83 | 34.36 | 32.89 | 33.22 | 794,500 |